Amalgamated Bank Has $11.54 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Amalgamated Bank lowered its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,370 shares of the medical research company's stock after selling 10,327 shares during the period. Amalgamated Bank's holdings in Edwards Lifesciences were worth $11,542,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in EW. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company's stock valued at $3,577,163,000 after purchasing an additional 325,808 shares during the period. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company's stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the period. Northern Trust Corp boosted its stake in shares of Edwards Lifesciences by 3.9% in the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company's stock valued at $440,446,000 after purchasing an additional 241,347 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its stake in shares of Edwards Lifesciences by 16.8% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company's stock valued at $312,625,000 after purchasing an additional 590,000 shares during the period. Finally, Ownership Capital B.V. boosted its stake in shares of Edwards Lifesciences by 21.3% in the fourth quarter. Ownership Capital B.V. now owns 3,489,915 shares of the medical research company's stock valued at $266,106,000 after purchasing an additional 613,817 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.19 during trading hours on Friday, reaching $85.25. The stock had a trading volume of 2,327,197 shares, compared to its average volume of 3,001,614. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The firm has a 50-day simple moving average of $90.08 and a 200-day simple moving average of $79.33. The firm has a market capitalization of $51.37 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 3.58 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analysts' expectations of $1.58 billion. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research analyst reports. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a "neutral" rating in a research note on Friday, April 26th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating on the stock in a research note on Friday, April 26th. Oppenheimer increased their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a research note on Monday, March 18th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research note on Thursday, March 7th. Finally, Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an "overweight" rating in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $92.71.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now owns 19,074 shares of the company's stock, valued at approximately $1,809,931.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares of the company's stock, valued at $14,639,824.29. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 237,749 shares of company stock valued at $20,920,934. Company insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.